中山大学张辉研究小组发现，基于SARS-CoV-2受体结合结构域（RBD）和七肽重复序列（HR）的纳米疫苗可引发强大的保护性免疫反应。2020年11月25日，《免疫》杂志在线发表了这项成果。

Title: Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Author: Xiancai Ma, Fan Zou, Fei Yu, Rong Li, Yaochang Yuan, Yiwen Zhang, Xiantao Zhang, Jieyi Deng, Tao Chen, Zheng Song, Yidan Qiao, Yikang Zhan, Jun Liu, Junsong Zhang, Xu Zhang, Zhilin Peng, Yuzhuang Li, Yingtong Lin, Liting Liang, Guanwen Wang, Yingshi Chen, Qier Chen, Ting Pan, Xin He, Hui Zhang

Issue&Volume: 2020-11-25

Abstract: Various vaccine strategies have been proposed in response to the global COVID-19 pandemic, each with unique strategies for eliciting immune responses. Here, we developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain (RBD) and/or heptad repeat (HR) subunits of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. Compared to monomer vaccines, nanoparticle vaccines elicited more robust neutralizing antibodies and cellular immune responses. RBD and RBD-HR nanoparticle vaccinated hACE2 transgenic mice vaccinated with RBD and/or RBD-HR nanoparticles exhibited reduced viral load in the lungs after SARS-CoV-2 challenge. RBD-HR nanoparticle vaccines also promoted neutralizing antibodies and cellular immune responses against other coronaviruses. The nanoparticle vaccination of rhesus macaques induced neutralizing antibodies, and T and B cell responses prior to boost immunization; these responses persisted for more than three months. RBD- and HR-based nanoparticles thus present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.

DOI: 10.1016/j.immuni.2020.11.015

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30502-1